PHARMACEUTICAL COMPOSITION COMPRISING ACTIVATION T CELLS SPECIFIC TO K-RAS FOR PREVENTING AND TREATING LUNG ADENOCARCINOMA AND PREPARATION METHOD THEREFOR

Title:

PHARMACEUTICAL COMPOSITION COMPRISING ACTIVATION T CELLS SPECIFIC TO K-RAS FOR PREVENTING AND TREATING LUNG ADENOCARCINOMA AND PREPARATION METHOD THEREFOR

Document Type and Number:

WIPO Patent Application WO/2023/128380

Kind Code:

A1

Abstract:

A pharmaceutical composition comprising activation T cells specific to K-ras for preventing and treating lung adenocarcinoma, according to the present invention, uses, as an antigen composition, a K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptide, which is designed such that a total of 12 epitopes (n= 1 to 12, and the last epitope (n=12) consists of 23 amino acids) in units of 30 amino acids sequentially in the amino acid sequence of K-ras are distinguished, and the sequence of 15 amino acids overlaps between epitopes. Accordingly, there are advantages of being more effective in recognizing and killing lung adenocarcinoma in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Therefore, when the pharmaceutical composition according to the present invention comprising activation T cells specific to K-ras for preventing and treating lung adenocarcinoma is used, there are advantages of being able to effectively prevent and treat lung adenocarcinoma, specifically, lung large cell adenocarcinoma, in which K-ras and K-ras mutants are detected.

More Like This:

JP2023512547	Autologous cancer antigen-reactive CD8 T cell isolation method using CD71 and its application
JP2021522208	Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8ab and class 1 restricted T cell receptors
WO/2024/062047	IL-21 FUSION PROTEINS USEFUL AS ENHANCERS OF ANTI-CANCER IMMUNOTHERAPIES

Inventors:

LEE WANG JUN (KR)
MOON HYOUN JONG (KR)
LIM SUN KI (KR)

Application Number:

PCT/KR2022/019967

Publication Date:

July 06, 2023

Filing Date:

December 08, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

MYONGJI HOSPITAL (KR)

International Classes:

A61K35/17; A61P35/00; C12N5/0783

Foreign References:

KR20170122270A	2017-11-03
KR20180081532A	2018-07-16
KR20170096199A	2017-08-23
CN112646024A	2021-04-13
CN112300269A	2021-02-02

Other References:

DATABASE Protein 2 May 1996 (1996-05-02), ANONYMOUS : "protein Calu1 Ki-ras ", XP093074275, retrieved from NCBI Database accession no. 0909261A
DATABASE Protein 19 January 2018 (2018-01-19), ANONYMOUS : "GTPase KRas isoform X3 [Cavia porcellus] ", XP093074300, retrieved from NCBI Database accession no. XP_003470499.2

Attorney, Agent or Firm:

KIM, Jeong Hyeon (KR)

Download PDF:

View/Download PDF PDF Help

Previous Patent: PHARMACEUTICAL COMPOSITION COMPRISING K-RAS-SPECIFIC ACTIVATED T CELLS FOR PREVENTION AND TREATMENT ...

Next Patent: PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING MELANOMA COMPRISING K-RAS-SPECIFIC ACTIVATED ...